Refine
Year of publication
- 2018 (2) (remove)
Document Type
- Doctoral Thesis (2)
Language
- English (2) (remove)
Has Fulltext
- yes (2)
Is part of the Bibliography
- no (2)
Keywords
- Natural Products (1)
- Svetamycin (1)
- antimicrobial resistance (1)
Institute
Natural products are valuable sources for biologically active compounds, which can be utilized as pharmaceuticals. Thereby, the synthesis is based purely on biosynthetic grounds often conducted by so-called megaenzymes. One major biosynthetic pathway is the acetate pathway including polyketide and fatty acid synthesis, which encompass one of the largest classes of chemically diverse natural products. These have medicinal relevance due to their antibacterial, antifungal, anthelmintic, immunosuppressive and antitumor properties.
Due to the high structural and functional similarity between polyketide synthases and type I animal fatty acid synthases (FASs), FAS can serve as a paradigm for the whole class of multifunctional enzymes. To fully exploit the biosynthetic potential of FASs, a good access to the enzyme is of essential importance. In this regard, Escherichia coli remains an unchallenged heterologous host due to low culturing costs, particularly fast mutagenesis cycles and relatively easy handling. Surprisingly, no sufficient expression strategy for an animal FAS in E. coli has yet been reported, as it turned out that the only approach was not reproducible.
We commenced our analysis with searching for an appropriate FAS homolog that fulfills our requirements of high protein quality, sufficient yield and ensured functionality. After extensive screening of different variants, culturing conditions and co-expression strategies, we identified the murine FAS (mFAS) as our protein of choice. The established purification strategy using tags at both termini led to a reproducible and sufficient access to the protein in excellent quality. The enzyme was further biochemically characterized including an enzyme kinetic investigation of fatty acid synthesis and an examination whether different acyl-CoA substrates can serve as priming units. This adds mFAS to our repertoire of manageable megaenzymes paving the way to exploit the catalytic efficiency in regards of microbial custom-compound synthesis.
With a strong focus on deepening our understanding of the working mode of such megaenzymes, rather than analyzing respective biosynthetic products, we have addressed the question whether mFAS itself can be engineered towards PKSs or whether properties of mFAS can be exploited to engineer PKSs. This approach was conducted on three levels of complexity from function of individual domains via organization of domains to form modules to the interplay of two modules in bimodular constructs.
Fatty acid synthesis begins with the loading of acyl moieties onto the FAS, which is conducted by a domain called malonyl-/acetyltransferase (MAT). This domain was in-depth characterized due to its important role of choosing the substrates that are built in the final compound. Our analysis comprised structural and functional aspects providing crystal structures of two different acyl-bound states and kinetic parameters for the hydrolysis and transacylation reaction using twelve exemplary CoA-esters. For this purpose, we have successfully established a continuous fluorometric assay using the α-ketoglutarate dehydrogenase as a coupled enzyme, which converts the liberated coenzyme A into Nicotinamide adenine dinucleotide. These data revealed an extensive substrate ambiguity of the MAT domain, which had not been reported to that extent before. Further, we could demonstrate that the fold fulfills both criteria for the evolvability of an enzyme by expressing MAT in different structural arrangements (robustness) and by altering the substrate ambiguity within a mutagenesis study (plasticity). Taken these aspects together, we are persuaded that the MAT domain can serve as a versatile tool for PKSs engineering in potential FAS/PKS hybrid systems.
On the higher level of complexity, we investigated the architectural variability of the mFAS fold, which constitutes a fundamental basis for a broader biosynthetic application. We could rebuild all four module types occurring in typical modular PKSs confirming a high degree of modularity within the fold. Not only structural, but also functional integrity of these modules was validated by using triacetic acid lactone formation and ketoreductase activity. Especially the latter analysis, made it possible to quantify effects of the engineering within the processing part by respective enzyme kinetic parameters. Expanding our focus beyond a singular module, we have utilized the mFAS fold for designing up to 380 kDa large bimodular constructs. In this approach, a loading didomain was attached N-terminally containing an additional MAT and acyl carrier protein (ACP) domain. Two constructs could be expressed and purified in excellent quality to investigate the influence of an altered overall architecture on fatty acid synthesis. By comparison with appropriate controls, a functional effect of the additional loading module could indeed be proven in the bimodular systems. Those constructs allow a comprehensive analysis of the underlying molecular mechanism in the future and serve as a potential model system to study the transition from iterative to vectorial polyketide synthesis in vitro.
In the 'Golden Age of Antibiotics', between 1940 and 1970, the global pharmaceutical companies discovered many antibiotics, such as cephalosporins, tetracyclines, aminoglycosides, glycopeptides, etc., as well as antifungal and antiparisitic agents. Due to several reasons, e.g. the steady re-discovery of already known NPs and the associated high costs, many pharmaceutical companies have significantly scaled back or totally abandoned their NP discovery programs since the late 20th century. Instead those companies started to focus on drug discovery based on combinatorial synthesis and thereby on the creation of enormous synthetic libraries containing small molecules. Unfortunately, this synthetic approach dealing with the optimization of existing NP or antibiotic has its limitations. As a result, leading pharmaceutical companies are re-conducting NPs research to discover new antimicrobials for the upcoming antimicrobial resistance threat. The Natural Product Center of Excellence, a collaboration between Sanofi-Aventis and Fraunhofer IME, is advancing in this context the discovery and development of novel antimicrobial agents for the treatment of infectious diseases through the testing of Sanofi's microbial extract library and strain collection. The aim of the present PhD thesis was the discovery and isolation of novel antimicrobial compounds with improved activities and/or novel MOAs as potential lead compound for a further drug discovery.